Power granulocytic leukaemia: comparability of radiotherapy and busulphan remedy. Report of the Medical Analysis Council’s working social gathering for therapeutic trials in leukaemia. Br Med J. 1968;1:201–8
Legislation AD, Kim DDH, Lipton JH. Being pregnant: a part of life in persistent myelogenous leukemia. Leuk Lymphoma. 2017;58:280–7.
Robertson HF, Apperley JF. Therapy of CML in being pregnant. Hematol Am Soc Hematol Educ Program. 2022;2022:123–8.
Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and being pregnant in persistent myeloid leukemia: opinion, proof, and suggestions. Ther Adv Hematol. 2020;11:2040620720966120.
Chelysheva E, Turkina A. Dangers and challenges of CML administration throughout being pregnant: searching for a balanced choice. Eur J Hematol. 2019;102:378–9.
Berdman E. Household planning and being pregnant in sufferers with persistent myeloid leukemia. Curr Hematol Malignancy Rep. 2023;18:1–7.
Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The results of imatinib on being pregnant end result. Blood. 2008;111:5505–8.
Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impression of dasatinib on being pregnant outcomes. Am J Hematol. 2015;90:1111–5.
Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M. Administration of pregnant persistent myeloid leukemia sufferers. Skilled Rev Hematol. 2016;9:781–91.
Cole S, Kantarjian H, Ault P, Cortés JE. Profitable completion of being pregnant in a affected person with persistent myeloid leukemia with out energetic intervention: a case report and assessment of the literature. Clin Lymphoma Myeloma. 2009;9:324–7.
Iqbal J, Ali Z, Khan AU, Aziz Z. Being pregnant outcomes in sufferers with persistent myeloid leukemia handled with imatinib mesylate: brief report from a growing nation. Leuk Lymphoma. 2014;55:2109–13.
Jovelet C, Seck A, Mir O, Simasotchi C, Broutin S, Goffinet F, et al. Variation in transplacental switch of tyrosine kinase inhibitors within the human perfused cotyledon mannequin. Ann Oncol. 2015;26:1500–4.
Chelysheva E, Turkina A, Polushkina E, Shmakov R, Zeifman A, Aleshin S, et al. Placental switch of tyrosine kinase inhibitors used for persistent myeloid leukemia remedy. Leuk Lymphoma. 2018;59:733–8.
Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical wire blood, placenta and breast milk. J Perinatol. 2007;27:241–3.
Abruzzese E, Aureli S, Bondanini F, Ciccarone M, Cortis E, Di Paolo A, et al. Power myeloid leukemia and being pregnant: when desires meet actuality. State-of-the-art, administration and end result of 41 instances, nilotinib placental switch. J Clin Med. 2022;11:1801.
Cortes JE, Gambacorti-Passerini C, Deininger M, Abruzzese E, De Annuntis L, Brümmendorf TH. Being pregnant outcomes in sufferers handled with bosutinib. Int J Hematol Oncol. 2020;9:IJH26.
Alizadeh H, Jaafar H, Rajnics P, Khan MI, Kajtár B. Consequence of being pregnant in persistent myeloid leukaemia sufferers handled with tyrosine kinase inhibitors: brief report from a single centre. Leuk Res. 2015;39:47–51.
Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, et al. A dramatic fetal end result following transplacental switch of dasatinib. Anticancer Medicine. 2012;23:754–7.
Lasica M, Willcox A, Burbury Ok, Ross DM, Branford S, Butler J, et al. The impact of tyrosine kinase inhibitor interruption and interferon use on being pregnant outcomes and long-term illness management in persistent myeloid leukemia. Leuk Lymphoma. 2019;60:1796–802.
Celiloglu M, Altunyurt S, Undar B. Hydroxyurea remedy for persistent myeloid leukemia throughout being pregnant. Acta Obstet Gynecol Scand. 2000;79:803–4.
Jain D, Atmapoojya P, Colah R, Lodha P. Sickle cell illness and being pregnant. Mediterr J Hematol Infect Dis. 2019;11:e2019040.
Rohilla M, Rai R, Yanamandra U, Chaudhary N, Malhotra P, Varma N, et al. Obstetric issues and administration in persistent myeloid leukemia. Indian J Hematol Blood Transfus. 2016;32:62–6.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 suggestions for treating persistent myeloid leukemia. Leukemia. 2020;34:966–84.
Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, et al. Administration of persistent myeloid leukemia throughout being pregnant amongst sufferers handled with a tyrosine kinase inhibitor: a single-Heart expertise. Leuk Lymphoma. 2021;62:909–17.
Claudiani S, Gatenby A, Szydlo R, Nesr G, Abulafia AS, Palanicawandar R, et al. MR4 sustained for 12 months is related to steady deep molecular responses in persistent myeloid leukemia. Haematologica. 2019;104:2206–14.
Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival contemplating disease-specific demise in sufferers with persistent myeloid leukemia. Leukemia. 2016;30:48–56.
Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, et al. Imatinib use throughout being pregnant and breast feeding: a case report and assessment of the literature. Arch Gynecol Obstet. 2009;280:169–75.
Burwick RM, Kuo Ok, Brewer D, Druker BJ. Maternal, fetal, and neonatal imatinib ranges with remedy of persistent myeloid leukemia in being pregnant. Obstet Gynecol. 2017;129:831–4.
Egbe A, Uppu S, Lee S, Stroustrup A, Ho D, Srivastava S. Congenital malformations within the new child inhabitants: a inhabitants research and evaluation of the impact of intercourse and prematurity. Pediatr Neonatol. 2015;56:25–30.
Homma S, Messé SR, Rundek T, Solar YP, Franke J, Davidson Ok, et al. Patent foramen ovale. Nat Rev Dis Prim. 2016;2:15086.
Tripathi R, Mazmudar RS, Knusel KD, Ezaldein HH, Belazarian LT, Bordeaux JS, et al. Influence of congenital cutaneous hemangiomas on new child care in the USA. Arch Dermatol Res. 2021;313:641–51.
Stirnemann J, Villar J, Salomon LJ, Ohuma E, Ruyan P, Altman DG, et al. Worldwide estimated fetal weight requirements of the INTERGROWTH-21st Challenge. Ultrasound Obstet Gynecol. 2017;49:478–86.
Damhuis SE, Ganzevoort W, Gordijn SJ. Irregular fetal progress: small for gestational age, fetal progress restriction, massive for gestational age: definitions and epidemiology. Obstet Gynecol Clin N Am. 2021;48:267–79.
Al Kindi S, Dennison D, Pathare A. Imatinib in being pregnant. Eur J Haematol. 2005;74:535–7.
Barron SL. Birthweight and ethnicity. Br J Obstet Gynaecol. 1983;90:289–90.
Urquia ML. Variability in birthweight, birthweight charts, and opposed outcomes: Is the “proper measurement” the best query? Paediatr Perinat Epidemiol. 2019;33:433–5.
Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Marçal VM, et al. Fetal progress restriction: present information. Arch Gynecol Obstet. 2017;295:1061–77.
Romo A, Carceller R, Tobajas J. Intrauterine progress retardation (IUGR): epidemiology and etiology. Pediatr Endocrinol Rev. 2009;6:332–6.
Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparability of interferon-alpha with busulfan and hydroxyurea in persistent myelogenous leukemia. The German CML Research Group. Blood. 1994;84:4064–77.
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Evaluation of imatinib as first-line remedy of persistent myeloid leukemia: 10-year survival outcomes of the randomized CML research IV and impression of non-CML determinants. Leukemia. 2017;31:2398–406.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Lengthy-term advantages and dangers of frontline nilotinib vs imatinib for persistent myeloid leukemia in persistent section: 5-year replace of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54.
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Remaining 5-year research outcomes of DASISION: the dasatinib versus imatinib research in treatment-naive persistent myeloid leukemia sufferers trial. J Clin Oncol. 2016;34:2333–40.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. EuropeanLeukemiaNet suggestions for the administration of persistent myeloid leukemia: 2013. Blood. 2013;122:872–84.
Wooden WA, Lee SJ. Malignant hematologic ailments in adolescents and younger adults. Blood. 2011;117:5803–15.
Pemmaraju N, Cortes J. Power myeloid leukemia in adolescents and younger adults: affected person traits, outcomes and assessment of the literature. Acta Haematol. 2014;132:298–306.
Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, et al. Youthful sufferers with persistent myeloid leukemia do properly despite poor prognostic indicators: outcomes from the randomized CML research IV. Ann Hematol. 2014;93:71–80.
Staley EM, Simmons SC, Feldman AZ, Lorenz RG, Marques MB, Williams LA third, et al. Administration of persistent myeloid leukemia within the setting of being pregnant: when is leukocytapheresis acceptable? A case report and assessment of the literature. Transfusion. 2018;58:456–60.
Gangat N, Tefferi A. Myeloproliferative neoplasms and being pregnant: Overview and apply suggestions. Am J Hematol. 2021;96:354–66.
Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol. 2015;94:S195–207.
Mubarak AA, Kakil IR, Awidi A, Al-Homsi U, Fawzi Z, Kelta M, et al. Regular end result of being pregnant in persistent myeloid leukemia handled with interferon-alpha in 1st trimester: report of three instances and assessment of the literature. Am J Hematol. 2002;69:115–8.
Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Power myelogenous leukemia: a concise replace. Blood. 1993;82:691–703.
Quinta´s-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon remedy for sufferers with Philadelphia chromosome-negative myeloproliferative problems. Thromb Hemost. 2006;32:409–16.
Varytė G, Arlauskienė A, Ramašauskaitė D. Being pregnant and a number of sclerosis: an replace. Curr Opin Obstet Gynecol. 2021;33:378–83.
